Are You Choosing the Right Model? A Guide to Selecting Your Next Immuno-Oncology Model
Presented by Dr. Michelle Mack, Global Director, Scientific Engagement, Crown Bioscience Inc.
Recent regulatory approvals and fast-track designations have signified the coming of age of cancer immunotherapy as a treatment paradigm. Among experimental immunotherapies, monoclonal antibodies targeting immune regulation checkpoints e.g. cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) are demonstrating impressive clinical benefits in a range of cancer types. However, development of effective new immunotherapeutics still faces many challenges. Researchers are still unsure why some patients and diseases benefit from these treatments while others do not. It is also currently unknown how to maximize the benefits from these agents e.g. through combination therapy approaches or between targeting different immune checkpoints.
Determining the best experimental immunotherapy model is a major obstacle toward answering these questions and developing better treatments. At present, most commonly used experimental cancer models comprise of human tumors grown in immunocompromised mice, derived from either in vitro immortalized cancer cells (cell line derived xenografts) or patient tumors (patient-derived xenografts, or PDX). The lack of functional immunity in these immunodeficient mice has significantly hindered the research and development of new immunotherapy agents. Syngeneic and genetically engineered mouse models (GEMM) with functional murine immunity are available; however, each has their own benefits and limitations. As new models are also developed, with different capabilities, choosing the correct and relevant preclinical model is critical, particularly to recapitulate clinical treatments including combination therapies.
Watch This Webinar To Learn:
- The latest in vivo cancer pharmacology models and what to consider when choosing the proper model
- How these models are used to investigate combination regimens of multiple immuno-therapies and immunotherapeutics combined with other treatment modalities, which correspond to current clinical investigations
Watch The Webinar Now!
About The Presenter:
Michelle Mack, Director of Scientific Engagement at Crown Bioscience brings 15 years of previous Oncology R & D experience from Pfizer Inc., where she was a Senior Scientist in the Oncology Research Unit and served as a research project leader on oncology therapeutic programs. At Pfizer, she led cross-functional teams exploring approaches that included: small-molecule inhibitors, antibody drug conjugates and nanoparticle based therapeutics.
Michelle's scientific expertise span's the preclinical and translational space for multiple solid and hematological tumor indications. Throughout her professional career, Michelle has worked in Oncology, Immunology and Immuno-Oncology therapeutic areas. She has several high-impact peer-reviewed publications and has led discussions at multiple scientific conferences. Michelle obtained her undergraduate degree from Rochester Institute of Technology, Rochester, NY. She then received her M.S. in microbiology and is currently completing her Ph.D. in molecular biology from Seton Hall University.